164 related articles for article (PubMed ID: 34992039)
21. Fulvestrant-induced cell death and proteasomal degradation of estrogen receptor α protein in MCF-7 cells require the CSK c-Src tyrosine kinase.
Yeh WL; Shioda K; Coser KR; Rivizzigno D; McSweeney KR; Shioda T
PLoS One; 2013; 8(4):e60889. PubMed ID: 23593342
[TBL] [Abstract][Full Text] [Related]
22. Exploring the PROTAC degron candidates: OBHSA with different side chains as novel selective estrogen receptor degraders (SERDs).
Li Y; Zhang S; Zhang J; Hu Z; Xiao Y; Huang J; Dong C; Huang S; Zhou HB
Eur J Med Chem; 2019 Jun; 172():48-61. PubMed ID: 30939353
[TBL] [Abstract][Full Text] [Related]
23. Decursin and decursinol angelate inhibit estrogen-stimulated and estrogen-independent growth and survival of breast cancer cells.
Jiang C; Guo J; Wang Z; Xiao B; Lee HJ; Lee EO; Kim SH; Lu J
Breast Cancer Res; 2007; 9(6):R77. PubMed ID: 17986353
[TBL] [Abstract][Full Text] [Related]
24. Antiestrogenically active 2-benzyl-1,1-diarylbut-2-enes: synthesis, structure-activity relationships and molecular modeling study for flexible estrogen receptor antagonists.
Lloyd DG; Smith HM; O'Sullivan T; Knox AS; Zisterer DM; Meegan MJ
Med Chem; 2006 Mar; 2(2):147-68. PubMed ID: 16787364
[TBL] [Abstract][Full Text] [Related]
25. Synthesis of targeted dibenzo[b,f]thiepines and dibenzo[b,f]oxepines as potential lead molecules with promising anti-breast cancer activity.
Ansari MI; Hussain MK; Arun A; Chakravarti B; Konwar R; Hajela K
Eur J Med Chem; 2015 Jun; 99():113-24. PubMed ID: 26067208
[TBL] [Abstract][Full Text] [Related]
26. Structure-activity relationships of 2, 4-disubstituted pyrimidines as dual ERα/VEGFR-2 ligands with anti-breast cancer activity.
Luo G; Tang Z; Lao K; Li X; You Q; Xiang H
Eur J Med Chem; 2018 Apr; 150():783-795. PubMed ID: 29587221
[TBL] [Abstract][Full Text] [Related]
27. The enhanced antiproliferative response to combined treatment of trichostatin A with raloxifene in MCF-7 breast cancer cells and its relevance to estrogen receptor β expression.
Tu Z; Li H; Ma Y; Tang B; Tian J; Akers W; Achilefu S; Gu Y
Mol Cell Biochem; 2012 Jul; 366(1-2):111-22. PubMed ID: 22476901
[TBL] [Abstract][Full Text] [Related]
28. The Quest for Orally Available Selective Estrogen Receptor Degraders (SERDs).
Wang L; Sharma A
ChemMedChem; 2020 Nov; 15(22):2072-2097. PubMed ID: 32916035
[TBL] [Abstract][Full Text] [Related]
29. Expression of the CD59 Glycoprotein Precursor is Upregulated in an Estrogen Receptor-alpha (ER-α)-Negative and a Tamoxifen-Resistant Breast Cancer Cell Line In Vitro.
Xiong H; Jin X; You C
Med Sci Monit; 2018 Nov; 24():7883-7890. PubMed ID: 30391994
[TBL] [Abstract][Full Text] [Related]
30. Design, synthesis and molecular docking studies of thymol based 1,2,3-triazole hybrids as thymidylate synthase inhibitors and apoptosis inducers against breast cancer cells.
Alam MM; Malebari AM; Syed N; Neamatallah T; Almalki ASA; Elhenawy AA; Obaid RJ; Alsharif MA
Bioorg Med Chem; 2021 May; 38():116136. PubMed ID: 33894490
[TBL] [Abstract][Full Text] [Related]
31. Estrogen-mediated inactivation of FOXO3a by the G protein-coupled estrogen receptor GPER.
Zekas E; Prossnitz ER
BMC Cancer; 2015 Oct; 15():702. PubMed ID: 26470790
[TBL] [Abstract][Full Text] [Related]
32. Development and therapeutic options for the treatment of raloxifene-stimulated breast cancer in athymic mice.
O'Regan RM; Osipo C; Ariazi E; Lee ES; Meeke K; Morris C; Bertucci A; Sarker MA; Grigg R; Jordan VC
Clin Cancer Res; 2006 Apr; 12(7 Pt 1):2255-63. PubMed ID: 16609042
[TBL] [Abstract][Full Text] [Related]
33. Development of novel tetrahydroisoquinoline-hydroxamate conjugates as potent dual SERDs/HDAC inhibitors for the treatment of breast cancer.
Luo G; Lin X; Ren S; Wu S; Wang X; Ma L; Xiang H
Eur J Med Chem; 2021 Dec; 226():113870. PubMed ID: 34610548
[TBL] [Abstract][Full Text] [Related]
34. Structure-function relationships of the raloxifene-estrogen receptor-alpha complex for regulating transforming growth factor-alpha expression in breast cancer cells.
Liu H; Park WC; Bentrem DJ; McKian KP; Reyes Ade L; Loweth JA; Schafer JM; Zapf JW; Jordan VC
J Biol Chem; 2002 Mar; 277(11):9189-98. PubMed ID: 11751902
[TBL] [Abstract][Full Text] [Related]
35. Raloxifene inhibits growth of RT4 urothelial carcinoma cells via estrogen receptor-dependent induction of apoptosis and inhibition of proliferation.
Hoffman KL; Lerner SP; Smith CL
Horm Cancer; 2013 Feb; 4(1):24-35. PubMed ID: 22965848
[TBL] [Abstract][Full Text] [Related]
36. Design and molecular modeling of novel P38α MAPK inhibitors targeting breast cancer, synthesized from oxygen heterocyclic natural compounds.
Abdelhafez OM; Ahmed EY; Abdel Latif NA; Arafa RK; Abd Elmageed ZY; Ali HI
Bioorg Med Chem; 2019 Apr; 27(7):1308-1319. PubMed ID: 30792101
[TBL] [Abstract][Full Text] [Related]
37. Synthesis and biological evaluation of 3-aryl-quinolin derivatives as anti-breast cancer agents targeting ERα and VEGFR-2.
Li X; Wu C; Lin X; Cai X; Liu L; Luo G; You Q; Xiang H
Eur J Med Chem; 2019 Jan; 161():445-455. PubMed ID: 30384047
[TBL] [Abstract][Full Text] [Related]
38. Triptolide inhibits human breast cancer MCF-7 cell growth via downregulation of the ERα-mediated signaling pathway.
Li H; Pan GF; Jiang ZZ; Yang J; Sun LX; Zhang LY
Acta Pharmacol Sin; 2015 May; 36(5):606-13. PubMed ID: 25864647
[TBL] [Abstract][Full Text] [Related]
39. Discovery of Novel ERα and Aromatase Dual-Targeting PROTAC Degraders to Overcome Endocrine-Resistant Breast Cancer.
Xin L; Wang C; Cheng Y; Wang H; Guo X; Deng X; Deng X; Xie B; Hu H; Min C; Dong C; Zhou HB
J Med Chem; 2024 Jun; 67(11):8913-8931. PubMed ID: 38809993
[TBL] [Abstract][Full Text] [Related]
40. Development of hybrid small molecules that induce degradation of estrogen receptor-alpha and necrotic cell death in breast cancer cells.
Okuhira K; Demizu Y; Hattori T; Ohoka N; Shibata N; Nishimaki-Mogami T; Okuda H; Kurihara M; Naito M
Cancer Sci; 2013 Nov; 104(11):1492-8. PubMed ID: 23992566
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
